133 results about "Post infection" patented technology

The invention discloses application of astaxanthin as a feed additive in improving the disease resistance of macrobrachium rosenbergii, and belongs to the field of feed additives. According to the method, astaxanthin is supplemented in the feed, the survival rate of the juvenile macrobrachium rosenbergii after being infected with DIV1 is increased, meanwhile, the abundance of pathogenic bacteria in intestinal tracts after the macrobrachium rosenbergii is infected with DIV1 is reduced, then the purpose of preventing disease outbreak of the macrobrachium rosenbergii caused by DIV1 can be achieved, and the method is a sustainable and effective method for preventing and treating the macrobrachium rosenbergii DIV1 disease.

The invention discloses an alternative virus infection model capable of being used for simulating human Marburg virus disease symptoms under BSL-2 as well as an establishment method and application of the alternative virus infection model, and belongs to the technical field of biology. According to the invention, firstly, a recombinant vesicular stomatitis virus (VSV-MARV / GP) for expressing Marburg virus glycoprotein is constructed, and the VSV-MARV / GP is used as an alternative virus to cause lethal infection of a narrative hamster. The pathogenicity of the VSV-MARV / GP has species specificity, age correlation, gender correlation and attack pathway dependency. After infection of VSV-MARV / GP, female narrative hamsters of 5 weeks old show weight loss, multiple organ failure, high virus load and other symptoms and develop into serious systemic diseases similar to those observed by human MARV patients, and all animals die within two to three days after infection. The model provided by the invention can be used as an effective tool for carrying out rapid preclinical evaluation on medical countermeasures of MARV under the BSL-2 condition.

The invention discloses a surface antigen gene StSAG1 of Sarcocystis tenella, the nucleotide sequence of the surface antigen gene StSAG1 is as shown in SEQ ID NO: 1, and according to the analysis result of protein antigenicity and antigen epitope, the 686 bp-1175 bp segment of the StSAG1 gene is selected to construct a recombinant protein expression vector and engineering bacteria; the antigen disclosed by the invention has very strong antigenicity and specificity, and can be subjected to effective antigen-antibody reaction with an antibody generated in serum after sheep (Ovis aries) is infected with sarcosporidium tenella, so that diagnosis is realized; low-titer antibodies can be detected two weeks after infection, and the detection window period is obviously advanced; by adopting the ELISA detection method, a visual result can be directly obtained. The method breaks through the limitation of an infection window period, has the advantages of low cost, high sensitivity, simplicity and convenience in operation, no need of expensive instruments and analysis and the like, is suitable for field detection in primary laboratories and pastures, and is beneficial to industrial production and market popularization and application.

[00121] The present invention relates to a label-free, high throughput method for determining an infectious virus titer in an aqueous sample comprising infectious virus, wherein the method comprises detecting the kinetics of morphological cell alteration, such as cell rounding, following viral infection, determining a parameter defining the curve of the morphological cell alteration as a function of time post infection and determining the infectious virus titer based on a standard curve of the infectious virus at a known infectious titer.

The invention belongs to the technical field of fish disease prevention and treatment, and particularly relates to application of chlorogenic acid in preparation of a product for preventing and treating GCHV viral inflammation. The regulation and control effects of chlorogenic acids with different concentrations (0.1%, 0.5% and 1%) on inflammatory factors (TNF-alpha, IL-1beta and IL-16) infected by the GCRV II virus are systematically analyzed, and the condition that the expression of the inflammatory factors (TNF-alpha, IL-1beta and IL-16) is obviously inhibited from the third day to the seventh day after infection by 0.5% chlorogenic acid is found; 0.01), the effect of which is not statistically different from that of the blank group (CK) (pgt; 0.05) of the method. If the high-concentration group has proinflammatory effect inversion (IL-1beta superscript 15.4%, p = 0.031) on the ninth day, dose-dependent toxicity is prompted. Results show that 0.5% chlorogenic acid can effectively inhibit viral inflammatory response, and long-term use of high dosage of chlorogenic acid may cause immune disorder.

The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg / L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.

The invention relates to the technical field of veterinary biological products, and particularly discloses riemerella anatipestifer cRA / HeN2024, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.32898, the preservation date is December 4, 2024, the preservation unit is China General Microbiological Culture Collection Center, and the preservation address is Yard 1, Beichen West Road, Chaoyang District, Beijing. The riemerella anatipestifer cRA / HeN2024 is type 1 riemerella anatipestifer and is separated from fallopian tube exudate of 15-day-old sick chicken showing respiratory tract symptoms; the isolated strain has a far genetic evolution relationship with the existing duck-origin and goose-origin riemerella anatipestifer, and the inactivated vaccine prepared from the strain has excellent immunogenicity and can effectively prevent and treat air sacculitis, salpingitis and pericarditis after chicken is infected with RA.

The invention relates to a method for detecting activation of specific T cells after tuberculosis infection and application of the method. Specifically, the invention provides a reagent combination for detection, and the reagent combination comprises an anti-CD4 antibody (CD4 antibody), an anti-CD154 antibody (CD154 antibody), an IFN-gamma detection antibody and a tuberculosis specific antigen. According to the method, through peripheral whole blood collection, PBMC cell separation, T cell activation (activation), activation termination (blocking), antibody labeling, membrane rupture, fixation, intracellular cytokine dyeing, flow cytometry detection and result analysis and judgment, the ratio of the expression IFN-gamma cells in the CD4 + CD154 + cells can be rapidly and accurately determined, and by combining an ROC curve and a constructed judgment standard, the content of the IFN-gamma cells in the CD4 + CD154 + cells can be determined, and the content of the IFN-gamma cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells can be determined. And the sample to be detected is judged to be in a positive / negative / gray region, so that whether a patient is infected by the mycobacterium tuberculosis or not can be more accurately diagnosed, especially aiming at a whole blood sample from a special crowd.

The invention discloses application of Med26 gene / protein as a target spot in preparation of a medicine for preventing and / or treating BCG infection, and belongs to the technical field of biological medicine. Aiming at the technical problems that the host defense defect is caused by excessive death of macrophages when a host is infected with BCG, the research on the mechanism of regulating and controlling the macrophages to resist BCG infection by host genes is not perfect and the like at present, a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screening technology is utilized to discover the key effect of the Med26 gene for negatively regulating and controlling the survival of the macrophages in the BCG infection in a BCG infection model for the first time, so that the BCG infection resistance of the host is improved. And it is verified that the survival rate of the macrophage after BCG infection can be significantly improved through targeted inhibition of Med26 gene expression, and the BCG removing capacity of the macrophage is enhanced. The discovery of the invention provides a new target for research and development of drugs for preventing and / or treating BCG infection.

The invention discloses a real-time detection system and a monitoring and early warning method for African swine fever virus. The system comprises a latex microsphere labeled immunochromatography antibody detection card, a portable MINI-PCR instrument and a freeze-dried microsphere type fluorescent PCR detection reagent, the detection card takes the recombinant ASFV p30 protein as a target spot, antibody detection is completed within 10 minutes, the lowest detection limit is 1: 1024, and the specificity is greater than 99%; the PCR reagent adopts a double-primer double-probe design, and the lowest detection limit is 1 copy / microliter. According to the invention, through a collaborative process of antibody screening, nucleic acid detection and result evaluation, ASFV total infection cycle detection is realized, epidemic situation discovery time is advanced to 1-3 days after infection, and early warning response time is shortened by more than 60%; the system is simple to operate and low in cost, does not need professionals and laboratories, can be deployed in basic-level scenes such as pig farms and slaughter houses, effectively solves pain points of an existing detection system, and provides key technical support for prevention and control of African swine fever.

The invention relates to the technical field of aquatic product culture, and particularly discloses application of zinc in preparation of a product for preventing and treating siniperca chuatsi rhabdovirus infection. By adding a proper amount of zinc ions into a mandarin fish cell culture system or culture environment, the application of zinc after infection in forms of zinc sulfate and the like can significantly inhibit protein expression and virus proliferation of the mandarin fish rhabdovirus, and has no toxic or side effect on host cells within a certain concentration range. The novel nutritional immune prevention and control strategy which is safe, economical and easy to operate provides an effective means for prevention and control of siniperca chuatsi virus diseases, and has important application prospects and economic values.

The invention discloses a pharmaceutical composition for treating post-infection cough and a preparation method thereof. The traditional Chinese medicine composition provided by the invention dispels wind and freezes lung to relieve exterior syndrome, eliminates dampness and strengthens spleen to treat middle energizer and depresses qi and reduces phlegm to relieve cough, and the whole formula combines dredging and tonifying and orderly freeing and descending, and embodies the formula characteristics of simultaneous regulation of lung and spleen and simultaneous treatment of principal and subordinate symptoms. The medicines are matched to dispel lung channel wind to stop spasm, and also can dissipate dampness with aromatics, invigorate the spleen to eliminate phlegm sources, tonify qi to strengthen superficies to tonify deficiency, and achieve the effects of dispelling wind and ventilating lung, eliminating dampness and phlegm, depressing qi and relieving cough. The traditional Chinese medicine composition directly focuses on the pathogenesis of cough with wind evil with dampness and adverse rising of lung qi after infection, and can be used for treating the symptoms of cough with exuberant wind and dampness obstruction after infection, such as throat itching and cough, frequent and severe cough, sticky expectoration, chest distress, epigastric fullness, fatigue and the like. The invention provides a new treatment strategy for the post-infection cough, and has a wide clinical application prospect.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

The invention relates to the technical field of biological medicines, in particular to a maintenance solution for culturing influenza viruses as well as a preparation method and application of the maintenance solution. The maintenance liquid comprises a basic culture medium and effective components, the effective components comprise amino acids, vitamins, salts and a virus nutrition enhancer, and the virus nutrition enhancer is a microorganism induced culture extract. The extract is prepared by inoculating fermentation microbial bacteria, performing induced culture through a plant induction factor extract containing American ginseng, polygonum cuspidatum and golden cypress, and then performing autolysis and enzymolysis in the presence of compound metabolic regulatory factors, namely trichosalix A and N-acetylcysteine. The maintenance fluid can significantly enhance host cell metabolism, inhibit cell antiviral response and delay cell apoptosis after infection, so that the culture yield and process stability of influenza viruses are significantly improved under the condition of no dependence on serum.

The present invention relates to a pharmaceutical composition comprising creatine or physiologically acceptable derivatives and / or salts and or adducts thereof for use in the treatment of breathing difficulties, chest pain, body aches etc. after virus infection particularly in combination with breathing exercises. A further embodiment of the invention relates to the use of a composition comprising creatine or physiologically acceptable derivatives and / or salts and or adducts thereof as dietary supplement for preparation of a diet supporting the recovery from breathing difficulties, chest pain, body aches etc. by breathing exercises after a viral infection of the lungs or lower respiratory system.

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-CoV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS CoV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

This disclosure provides compositions and methods for treating and / or preventing monkeypox infection and / or symptoms post-infection, the method including administering a composition including at least one attenuated vaccinia virus, the at least one attenuated vaccinia virus including a modification to the coding sequence of E3L.

The invention provides a recombinant duck plague virus for expressing DTMUV virus-like particles as well as a construction method and application of the recombinant duck plague virus, and belongs to the field of medicines. The invention provides recombinant polynucleotide which is derived from a duck tembusu virus genome and is subjected to codon optimization by taking a duck as a host. According to the invention, the recombinant polynucleotide is inserted into pEP-BGH-end, and a plasmid pEP-pCMV-CME451 is constructed and obtained. According to the invention, pEP-pCMV-CME451 plasmid is taken as a template, and a recombinant exogenous expression cassette is inserted into a duck plague virus vaccine strain, so that recombinant duck plague mutant BAC clone is obtained. According to the invention, the BAC clone is also rescued. Compared with a control strain rE1, the rescue virus provided by the invention has a larger plaque area, and can detect corresponding DTMUV virus E protein and generate an antibody aiming at the E protein. Under a transmission electron microscope, after virus infection CEFs is saved, DTMUV C-M-E451 forms a virus-like particle structure.

The invention discloses application of neochlorogenic acid in preparation of a medicine for preventing and / or treating hand-foot-and-mouth disease caused by A16 type coxsackie virus (CVA16) infection, and belongs to the technical field of biological medicine. Researches prove that the neochlorogenic acid has the effect of resisting CVA16 infection on HEK293T cells and H4 cells, after the two cells treated by the neochlorogenic acid are infected by the CVA16, the viral genome RNA abundance is obviously reduced, and the cell lesion death condition is obviously relieved; meanwhile, a cytotoxicity test shows that the neochlorogenic acid has no obvious cytotoxicity to HEK293T cells and only has weak cytotoxicity to H4 cells. Therefore, in a reasonable dosage range, the neochlorogenic acid, which is a low-toxicity natural small molecule compound, can be used for preparing the anti-CVA16 medicine for preventing and / or treating the hand-foot-and-mouth disease caused by CVA16 infection.

Peptides generating antibodies to human immunodeficiency virus (HIV) post-infection were identified. Higher antibody reactivity to these peptides was associated, with lower viral load post-infection.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and methods for the treatment of post-acute infection disorders, including long COVID, long flu, and post-treatment Lyme disease syndrome.

The invention provides application of Hnf4alpha or a biological material containing Hnf4alpha in preparation of a product for inhibiting bacteria and / or viruses, and belongs to the technical field of biological medicines. In-vivo and in-vitro experiments show that overexpression of the Hnf4alpha not only can effectively prevent infection of aeromonas salmonicida and grass carp hemorrhagic disease viruses, but also can remarkably inhibit co-infection of the aeromonas salmonicida and the grass carp hemorrhagic disease viruses. The bacterial or virus load after infection is obviously reduced, and the activity of cells and the survival rate of juvenile fish are improved. The invention provides a molecular target for prevention and control of bacterial infectious diseases, virus infectious diseases and mixed infectious diseases of cyprinid fishes.

The invention relates to the technical field of biology, in particular to a modeling method for rapidly preparing a humanized monkey model, which comprises the following steps: S1, constructing an AAV9-ACE2-GFP vector, observing the expression condition of GFP, and detecting the expression condition of ACE2 in infected cells in combination with flow cytometry; s2, directionally infecting the lung of the mouse with an AAV9-ACE2 virus, and detecting the RNA expression level of human ACE2 to verify the expression effect of the AAV9-ACE2 virus in the mouse body; s3, the AAV-ACE2 virus is targeted to the lung organ of the monkey, and the expression quantity of the human ACE2 gene in the lung tissue is detected through Q-PCR; and S4, carrying out a novel coronavirus infection experiment by using the humanized monkey model obtained in the step S3. The method comprises the following steps: firstly, establishing a virus delivery mode to carry out humanization on lungs of non-human primates; the genetically modified monkey is further subjected to a challenge experiment, a monkey model more susceptible to novel coronavirus is prepared, and a humanized monkey can be rapidly generated to be used for evaluating novel coronavirus related drugs.

The invention relates to the technical field of virus gene engineering, in particular to a construction method of a porcine respiratory syndrome virus, which comprises the following steps: taking a PRRSV HEB1 strain genome (GenBankEF112447.1) as a template, modifying the template, cloning the modified genome to a pBAC11 vector, and rescuing a recombinant virus rPRRSV-HA-CMV-mC through in vitro transcription and Marc-145 cell transfection. The recombinant PRRSV strain shows remarkable replication delay and titer reduction, and an attenuated phenotype is formed. The recombinant virus and an ISA206 oil adjuvant are further emulsified to prepare the vaccine, the vaccine shows efficient immunogenicity in piglet immunization, clinical symptoms, viremia and lung pathological injury after PRRSV infection can be remarkably reduced, and the vaccine has the potential of being developed into a safe and effective vaccine.

The application discloses double-stranded RNA for killing schistosoma and application thereof, wherein the nucleotide sequence of the positive strand of the double-stranded RNA is shown as SEQ ID NO:1. Through animal experiments, the double-stranded RNA has good killing effect on the early infection establishment stage (1-30 dpi) of the worm body, the worm development stage (18-30 dpi) after infection establishment, and the mature worm stage (26-42 dpi) after infection establishment, can not only prevent schistosoma from establishing infection in the host body and effectively inhibit the growth and development of the worm body, but also can reduce the oviposition of female worms, even kill the worm body with established infection, and reduce the pathological damage to the host, has great treatment potential, and can be used for treating schistosoma infection at different development stages.

In some aspects, provided herein are compositions of and methods for utilizing a sterically stabilized liposome carrier encapsulating a selected drug for the delivery of such drug effectual in the treatment of a mammal infected by a virus, such as SARS-COV-2, specifically in inhibiting the viral replication and reducing symptoms including lung inflammation. The compositions and methods disclosed herein provide a potential treatment for COVID-19 with improved patient compliance as they offer a less frequent dosing for the “long haulers” post COVID-19 initial infection.

The present application belongs to the field of biomedical technology, and relates to a human papilloma virus (HPV) infection immune response related detection method and application. The present application provides a new method for detecting HPV infection, which comprises detecting virus load, DC maturation state in peripheral blood, or T lymphocyte subgroups and NK cell surface markers. The present application adopts a combined detection technology of DC cells, T lymphocytes and NK cells, and is used for detecting the immune response state of a host after HPV infection. The present application also provides application of the detection method. The detection method of the present application is simple and clear in result, and can be applied to clinical auxiliary detection and examination of HPV and even cervical cancer, and screening of HPV and even cervical cancer.

The invention relates to an external traditional Chinese medicine composition for treating wind-evil-in-lung type post-infection cough, which is prepared from the following raw material medicines in parts by weight: 4-8 parts of honey-fried ephedra, 13-17 parts of semen armeniacae amarae, 7-11 parts of radix asteris, 7-11 parts of cynanchum glaucescens, 7-11 parts of platycodon grandiflorum, 10-14 parts of herba ardisiae japonicae, 7-11 parts of oroxylum indicum, 13-17 parts of divaricate saposhnikovia root, 10-14 parts of schizonepeta and 1-5 parts of honey-fried licorice root. The traditional Chinese medicine composition is acupoint application. The invention further provides application of the external traditional Chinese medicine composition. After treatment, the curative effect is evaluated according to the cough symptom integral, the effective rate of a treatment group is 88.57%, and the effective rate of a control group is 77.14%. After treatment, after intervention, the scores of cough, expectoration, bucking, throat itching and cough and severe cough caused by external conditions of cough patients caused by wind pathogen in the lung type infection are all reduced in a treatment group, and the scores are superior to those of a control group. After treatment and intervention, serum CRP levels of a treatment group and a control group are reduced, and the change of the treatment group before and after intervention is superior to that of the control group.

The invention relates to the technical field of biological medicine, in particular to a construction method and application of a respiratory virus infected alveolar organ model. Comprising the following steps: infecting alveolar cell source single cells by using a virus inoculum, coating the infected alveolar cell source single cells with matrigel, and inoculating the infected alveolar cell source single cells into a first culture medium for three-dimensional culture to obtain the respiratory virus infected alveolar organ model. According to the invention, alveolar cells are creatively applied to model characterization of respiratory virus infection, and particularly, alveolar cell source single cells are subjected to infection treatment by adopting influenza A H1N1 virus, so that the constructed model can well simulate and characterize the infection process of influenza A virus in human lung organs; the method provides an experimental basis for drug research and development (such as high-throughput screening of anti-influenza virus drugs), viral disease pathogenesis research, research on defense mechanisms of naturally occurring virus infection or virus infection caused by experiments and the like, and has important guiding significance.

The invention provides an O-type foot-and-mouth disease nanoparticle antigen NP-OVPn as well as a preparation method and application thereof. The NP-OVPn provided by the invention is obtained by the following steps: after intracellular self-assembled O-type foot-and-mouth disease nanoparticle antigen NP-OVPn-T is subjected to TEV enzyme cleavage, removing T fusion-promoting tag protein through nickel affinity chromatography purification, and enabling antigen epitopes to be fully exposed on the surface of nanoparticle carrier protein NP. According to the FMDV O-type NP-OVPn nanoparticle antigen, three structural proteins of FMDV O-type VP1, VP2 and VP3 are displayed at the same time in the form of nanoparticles, the FMDV O-type NP-OVPn nanoparticle antigen can well and uniformly react with antibodies generated after immunization or infection of three animals including pigs, cattle and sheep, and the problem that the source of the FMDV O-type antigen is limited in FMDV clinical diagnosis is solved. The invention also provides a vaccine developed on the basis of the NP-OVPn nanoparticle antigen, and an FMDV O-type LB-ELISA antibody detection kit. The kit can be simultaneously used for quantitative detection of FMDV O-type specific antibodies from three different animals, namely pigs, cows and sheep, and has the advantages of high sensitivity, good specificity and high accuracy.